CapitalStars Financial Research Pvt Ltd


CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market.we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors.we provide intraday as well as delivery stock tips in NSE and BSEand commodity tips in MCX and NCDEX. Read More

Commodity Market Services

Commodity Market Services

In this service we provide 3-4 intraday calls in MCX with a high level of accuracy. The calls are given in Precious Metals, Base Metals and Energies. You can also avail Free Tips for two days to test our accuracy and if satisfied you can join the services with Capital Stars. Read More

Nifty Market Services

Nifty Future Services

We provide you around 1-2 nifty calls, Bank Nifty Futures, nifty futures tips, sgx nifty tips Daily. You can gain more profit, Get 2 days free trial calls. Read More

Equity Market Services

Equity Market Services

In this service we provide 2-4 intraday stock cash calls in NSE/BSE with a high level of accuracy.You can also avail Free Stock Tips for two days to test our accuracy and if satisfied you can join stock cash services with Capital Stars. Read More

Register now

CapitalStars provides Free Trial in Intraday as well as in Positional Services of Equity, Derivatives, and Commodities and Forex Markets. We provide recommendations in NSE, BSE, MCX, NCDEX, and MCX-SX etc. We render you enough entry and exit time in our calls so clients can easily maximize their profits. Read More

Wednesday, 29 March 2017

Dishman Pharma hits new high; stock surges over 35% in two days : 29 Mar 2017

Dishman Pharmaceuticals and Chemicals hit a fresh record high of Rs 322, up 16% on BSE on back of heavy volumes after the company on Tuesday said that its partner Tesaro Inc received US Food and Drug Administration (FDA) nod for cancer drug Zejula capsules.

The stock of drug maker has rallied 39% in past two trading sessions from Rs 232 on March 27, 2017.

“We believe that the increase in the stock price is based upon market estimation that we are one of the suppliers of the API for "Zejula" capsules, which got approved by the US FDA as per the press release given by Tesaro lnc,” Dishman Pharma said in a regulatory filing.

Since the company does not manufacture the innovator's end product in CRAMS segment, it is Tesaro lnc., which has received the US FDA approval for cancer drug Zejula Capsules, it added.

At 09:30 am; the stock was up 12% at Rs 310 as compared to 0.15% rise in the S&P BSE Sensex. The trading volumes on the counter surged more than five-fold with a combined 6.86 million shares changed hands on the BSE and NSE so far.

Capitalstars Financial Research Private Limited is a research house and an investment advisory carrying out operations in the Indian Equities and Commodity market.We also provide 2 days free trial to our client.Join our services and trade with us. 
* Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
* CapitalStars Investment Adviser: SEBI Registration Number: INA000001647


Post a Comment